Abstract Library

#4531 The role of metabolism in neuroendocrine tumour cell models and patients

Introduction: It is recognised that the adipose tissue plays a major role in cancer through a metabolic coupling that supports tumour cell growth. Recent evidence suggests that altered metabolic pathways drive the development and influence the clinical outcomes of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: tumour metabolism, adipocytes, RNA-sequencing, GEP-NET,

#4406 Fluorescence labelled plasma derived small extracellular vesicle as biomarkers in metastatic pancreatic neuroendocrine tumour patients

Introduction: Pancreatic neuroendocrine tumours (PanNET) are rare with increased annual incidence rate 1/lac. There are no specific biomarkers, diagnostic and prognostic tests available for PanNET. The small extracellular vesicles (sEV) play a key role in tumour growth and metastasis and can be a potential biomarker for metastasis of PanNET.

Conference:

Presenting Author:

Authors: As S, Gorai P, Naik M, Kumar R, Kumar S,

Keywords: Metastasis, Pancreatic neuroendocrine tumour, Small extracellular vesicles, Fluorescence, Nanoparticle tracking analysis,

#4224 Uncommon manifestations in type 4 familial paraganglioma syndrome – A large cohort of patients harbouring the SDHB p.Q214Ter variant

Introduction: Familial paraganglioma type 4 syndrome (PPGL4) is caused by a germline pathogenic variant (PV) in the SDHB gene. Patients harbouring germline SDHB PV have a higher risk of developing paragangliomas and pheochromocytomas. PPGL4 is considered a higher-risk syndrome for aggressive, and metastatic, abdominal-thoracic paragangliomas compared with other familial paraganglioma syndromes.

Conference:

Presenting Author: Halperin R

Authors: Halperin R, Jabarin A, Tirosh A,

Keywords: paraganglioma, pheochromocytoma, sdhb, hereditary,

#4078 Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,

#4028 Clinical application of digital pathology: Proposal of a new G0 category useful in small intestinal NET (SI-NET)

Introduction: SI-NET display low proliferation rate despite a high frequency of metastases. Ki67 index is frequently reported as “

Conference:

Presenting Author: Couvelard A

Authors: Guedj N, Cléry G, Chassac A, Hentic O, Colnot N,

Keywords: Small Intestinal NET-, grade, survival, prognosis, G1,